A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia.

ABSTRACT:

Background and objectives

In clinical practice, physicians often use once-weekly (QW) and biweekly (Q2W) dosing of epoetin alfa to treat anemia in patients with chronic kidney disease (CKD). Although the literature supports this practice, previous studies were limited by short treatment duration, lack of randomization, or absence of the approved three times per week (TIW) dosing arm. This randomized trial evaluated extended dosing regimens of epoetin alfa, comparing QW and Q2W to TIW dosing in anemic CKD subjects. The primary objective was to show that treatment with epoetin alfa at QW and Q2W intervals was not inferior to TIW dosing.

Design, setting, participants, & measurements

375 subjects with stage 3 to 4 CKD were randomized equally to the three groups and treated for 4

SUBMITTER: Pergola PE 

PROVIDER: S-EPMC2774960 | biostudies-literature | 2009 Nov

REPOSITORIES: biostudies-literature